MAPT and Alzheimer disease: Incorporating actigraphy and olfactory testing into longitudinal studies using analyses that detect preclinical AD, such as cerebrospinal fluid biomarkers or amyloid beta and tau positron emission tomography imaging (Musiek et al., 2018), could reveal shared neural mechanisms that lead to better understanding of disease progression.